Kuo-Hsuan Hsu
Overview
Explore the profile of Kuo-Hsuan Hsu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
71
Citations
928
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sun R, Liao P, Liao Y, Yeh Y, Chiang C, Chen Y, et al.
J Chin Med Assoc
. 2025 Jan;
PMID: 39865515
Background: Limited information is available regarding the clinical features and outcomes of advanced human epidermal growth factor receptor 2 (HER2)-mutant non-small cell lung cancer (NSCLC) in Taiwan, despite expanding treatment...
2.
Peng M, Huang Y, Hsu K, Tseng J, Lee P, Chen K, et al.
Cancers (Basel)
. 2025 Jan;
16(24.
PMID: 39766072
Background/objectives: Osimertinib is a standard sequential therapy for advanced and recurrent Epidermal Growth Factor Receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC) patients with the T790M mutation, following treatment with first- or...
3.
Shen P, Chuang C, Lin C, Hsu Y, Huang Y, Hsu K, et al.
Oncol Lett
. 2024 Nov;
29(1):35.
PMID: 39512503
Patients with non-small cell lung cancer (NSCLC) and incomplete resection have poor clinical outcomes. The present study aimed to identify risk factors for disease progression and mortality. A total of...
4.
Ou W, Hsu K, Tseng J, Lee P, Chen K, Huang Y, et al.
Ther Adv Med Oncol
. 2024 Nov;
16:17588359241290718.
PMID: 39483140
Background: Bevacizumab is extensively used in the treatment of advanced non-small-cell lung cancer (NSCLC). Numerous clinical trials have proven the clinical efficacies of bevacizumab biosimilars (BB). Objective: Our study aimed...
5.
Lee P, Chen I, Chen Y, Hsiao T, Tseng J, Huang Y, et al.
JCO Precis Oncol
. 2024 Sep;
8:e2400236.
PMID: 39348659
Purpose: Low-dose computed tomography (LDCT) can help reducing lung cancer mortality. In Taiwan, the existing screening criteria revolve around smoking habits and family history of lung cancer. The role of...
6.
Lee P, Ou W, Huang Y, Hsu K, Tseng J, Chang G, et al.
Int J Mol Sci
. 2024 Jul;
25(13).
PMID: 39000058
Despite the widespread application of next-generation sequencing (NGS) in advanced lung adenocarcinoma, its impact on survival and the optimal timing for the examination remain uncertain. This cohort study included advanced...
7.
Huang Y, Chiu L, Tseng J, Hsu K, Chen C, Sheu G, et al.
Int J Mol Sci
. 2024 Jan;
25(1).
PMID: 38203787
Lung cancer is considered the number one cause of cancer-related deaths worldwide. Although current treatments initially reduce the lung cancer burden, relapse occurs in most cases; the major causes of...
8.
Wu J, Tseng J, Zheng Z, Chu C, Chen K, Lin M, et al.
Ther Adv Med Oncol
. 2024 Jan;
16:17588359231220606.
PMID: 38188463
Background: Patients with advanced ()-mutant lung adenocarcinoma (LAD) inevitably experience drug resistance following treatment with EGFR-tyrosine kinase inhibitors (TKIs). Objectives: We aimed to analyze the effect of primary tumor consolidative...
9.
Chang G, Chiu C, Yu C, Chang Y, Chang Y, Hsu K, et al.
Lancet Respir Med
. 2023 Dec;
12(2):141-152.
PMID: 38042167
Background: In Taiwan, lung cancers occur predominantly in never-smokers, of whom nearly 60% have stage IV disease at diagnosis. We aimed to assess the efficacy of low-dose CT (LDCT) screening...
10.
Ou W, Liao P, Hsu Y, Huang Y, Hsu K, Tseng J, et al.
Cancer Manag Res
. 2023 Nov;
15:1251-1262.
PMID: 37953889
Background: Antiangiogenetic therapy and lung cancer, per se, are associated with an increased risk of thromboembolic events (TE). We aim to evaluate the pattern and outcome of TE as well...